^
Association details:
| Biomarker: | MET exon 14 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | CKD-702 (c-MET inhibitor, EGFR antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
998P - A phase I study of CKD-702, an EGFR-cMET bispecific antibody, in advanced or metastatic non-small cell lung cancer (NSCLC)
Published date:
09/05/2022
Excerpt:
CKD-702 has a manageable safety profile related to EGFR and cMet inhibition, and showed preliminary response in patients with MET ex14 skipping.
Trial ID:
